New Glioblastoma Cancer Vaccine Shows Promise in Phase 2 Trial
Results of a multicenter Phase 2 clinical trial on a new brain cancer vaccine tailored to a patient’s own tumor show that the vaccine was safe and less toxic than conventional treatments and that it could extend survival for people with recurrent glioblastoma – a deadly type of brain cancer.